13F Data
13F filer · CIK 1834239

EQT Fund Management S.a r.l.

LUXEMBOURG, N4 · filing since Q2 2022 · last filing Aug 13, 2026
Reported value
$862.6M
$-158.1M vs prior
Positions
5
New / sold out
0 / 0
Added / reduced
2 / 0
Turnover
0.0%
buys $19.3M · sells $0
Top-10 weight
100.0%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
AddedOCULIS HOLDING AG+1,050,000+17.8%+$14.6M
AddedEVOMMUNE INC+358,680+7.3%+$4.8M

Biggest sells vs Q1 2026

No reduced or sold positions this quarter.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q2 2022: $775.0MQ3 2022: $399.0MQ4 2022: $0Q1 2023: $0Q2 2023: $0Q3 2023: $0Q3 2025: $1.9BQ4 2025: $1.1BQ1 2026: $1.0BQ2 2026: $862.6M
Q2 2022Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1WAYSTAR HLDG CORPCOM24,879,437$510.8M59.21%
2PHARVARIS N VCOM3,424,609$118.4M13.73%
3OCULIS HOLDING AGORDINARY SHARES6,950,294$96.4M11.18%
4EVOMMUNE INCCOM SHS5,288,313$70.3M8.15%
5AGOMAB THERAPEUTICS NVSPONSORED ADS5,141,992$66.7M7.74%